ctDNA testing post-surgery identifies high-risk stage 3 colon cancer patients more accurately than traditional staging methods. Detectable ctDNA correlates with a four- to six-fold increased risk of ...

In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...

But whether patients should be getting the tests—as some already are—is not yet clear. New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and ...